Skip to main content

Advertisement

Table 5 Characteristics of “adaptive” or “non-adaptive” patients

From: Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

Characteristics Adaptive patients Non-adaptive patients p-value
(n = 101) (n = 28)
No. (%) No. (%)
Age (years)
 Median (range) 65 (24–86) 67 (34–94) 0.09
Sex
 Male 51 (50) 17 (61) 0.34
 Female 50 (50) 11 (39)  
ECOG PS
 0 8 (8) 1 (4)  
 1 56 (55) 12 (43)  
 2 32 (32) 12 (43)  
 3 4 (4) 3 (11)  
 4 1 (1) 0 (0)  
 0–1 64 (63) 13 (46) 0.11
 2–4 37 (37) 15 (54)  
Disease status
 Advanced 92 (91) 28 (100) 0.10
 Recurrent 9 (9) 0 (0)  
Primary site
 Stomach 97 (96) 26 (93) 0.48
 GEJ 4 (4) 2 (7)  
No. of metastatic sites
 1–2 81 (80) 19 (68) 0.17
> 3 20 (20) 9 (32)  
Subtype of SPM
 Massive ascites 46 (45) 16 (57) 0.50
 Inadequate oral intake 28 (27) 7 (25)  
 Both 27 (27) 5 (18)  
Serum albumin level (g/ml)
 Median (range) 3.1 (1.8–4.4) 2.9 (2.0–4.2) 0.13
Serum CRP level (mg/dl)
 Median (range) 1.6 (0.0–20.7) 4.8 (0.1–24.0) < 0.01
  1. Patients who died within 90 days after treatment initiation were defined as “non-adaptive”
  2. Other patients were defined as “adaptive”
  3. CRP C-reactive protein, ECOG PS Eastern Cooperative Oncology Group performance status, GEJ gastroesophageal junction, SPM severe peritoneal metastasis